A stochastic model for primary HIV infection: optimal timing of therapy

被引:30
作者
Ribeiro, RM
Bonhoeffer, S
机构
[1] Friedrich Miescher Inst, CH-4002 Basel, Switzerland
[2] Univ Oxford, Dept Zool, Wellcome Trust Ctr Epidemiol & Infect Dis, Oxford OX1 3PS, England
[3] ETH Zentrum, Inst Expt Ecol, CH-8092 Zurich, Switzerland
基金
英国惠康基金;
关键词
primary infection; resistant mutant; stochastic model; timing of therapy;
D O I
10.1097/00002030-199902250-00007
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To investigate the optimal time point for the initiation of therapy in HIV infection from the perspective of drug resistance. Background: The enormous genetic diversity of HIV within an infected individual represents one of the greatest challenges for effective therapy, because the viral population may harbour drug-resistant mutants that rapidly outgrow the wild-type virus once the patient starts treatment. To determine the optimal timing of therapy it is crucial to know how long it takes for the viral population to build up sufficient diversity to enable the virus to escape from therapy. Method: A stochastic model of the viral diversification during primary infection was used to study the behaviour of small population sizes of mutant virus. Results and conclusions: The simulations suggest that from the perspective of viral diversity, therapy should be started at the viral set-point. Starting treatment earlier involves a risk of the selective outgrowth of drug-resistant mutants, which are transiently present at the viral peak during primary infection. (C) 1999 Lippincott Williams & Wilkins.
引用
收藏
页码:351 / 357
页数:7
相关论文
共 38 条
[1]  
Aber V, 1996, LANCET, V348, P283, DOI 10.1016/S0140-6736(96)05387-1
[2]   Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents [J].
Anderson, J ;
Armstead, R ;
Baker, AC ;
Barr, D ;
Bozzette, S ;
Cox, S ;
Delaney, M ;
Gordin, F ;
Greaves, W ;
Harrington, M ;
Henning, JJ ;
Hirsch, MS ;
Jacobs, J ;
Marlink, R ;
Maxwell, C ;
Mellors, JW ;
Nash, DB ;
Perryman, S ;
Schooley, RT ;
Sherer, R ;
Spector, SA ;
Torres, G ;
Volberding, P ;
Brady, BA ;
Cohen, O ;
Daniels, EM ;
Feigal, D ;
Feinberg, M ;
Gayle, HD ;
Graydon, TR ;
Kaplan, J ;
Macher, A ;
Martin, RF ;
Masur, H ;
Mofenson, L ;
Murray, J ;
O'Neill, J ;
Perez, LC ;
Riseberg, R ;
Shekar, S ;
Stanley, SK ;
Whitescarver, J ;
Carpenter, C ;
Bally, G ;
Rachlis, A ;
Stanley, SK ;
Brady, BA ;
Daniels, EM .
ANNALS OF INTERNAL MEDICINE, 1998, 128 (12) :1079-1100
[3]   Virus dynamics and drug therapy [J].
Bonhoeffer, S ;
May, RM ;
Shaw, GM ;
Nowak, MA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (13) :6971-6976
[4]  
Bonhoeffer S, 1997, P ROY SOC B-BIOL SCI, V264, P631
[5]   Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus [J].
Borrow, P ;
Lewicki, H ;
Wei, XP ;
Horwitz, MS ;
Peffer, N ;
Meyers, H ;
Nelson, JA ;
Gairin, JE ;
Hahn, BH ;
Oldstone, MBA ;
Shaw, GM .
NATURE MEDICINE, 1997, 3 (02) :205-211
[6]   HIV-1 BIOLOGICAL PHENOTYPE AND THE DEVELOPMENT OF ZIDOVUDINE RESISTANCE IN RELATION TO DISEASE PROGRESSION IN ASYMPTOMATIC INDIVIDUALS DURING TREATMENT [J].
BOUCHER, CAB ;
LANGE, JMA ;
MIEDEMA, FF ;
WEVERLING, GJ ;
KOOT, M ;
MULDER, JW ;
GOUDSMIT, J ;
KELLAM, P ;
LARDER, BA ;
TERSMETTE, M .
AIDS, 1992, 6 (11) :1259-1264
[7]   Report of the NIH Panel to Define Principles of Therapy of HIV Infection [J].
Carpenter, C ;
Feinberg, M ;
Aubry, W ;
Averitt, D ;
Coffin, J ;
Cooper, D ;
Follansbee, S ;
Hamburg, P ;
Harrington, M ;
Hidalgo, J ;
Jaffe, H ;
Landers, D ;
Masur, H ;
Pizzo, P ;
Richman, D ;
Saag, M ;
Schooley, R ;
Stone, V ;
Thompson, M ;
Trono, D ;
Vella, S ;
Walker, B ;
Yeni, P .
ANNALS OF INTERNAL MEDICINE, 1998, 128 (12) :1057-1078
[8]   Antiretroviral therapy for HIV infection in 1997 - Updated recommendations of the International AIDS Society USA panel [J].
Carpenter, CCJ ;
Fischl, MA ;
Hammer, SM ;
Hirsch, MS ;
Jacobsen, DM ;
Katzenstein, DA ;
Montaner, JSG ;
Richman, DD ;
Saag, MS ;
Schooley, RT ;
Thompson, MA ;
Vella, S ;
Yeni, PG ;
Volberding, PA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (24) :1962-1969
[9]   HIV infection induces changes in CD4(+) T-cell phenotype and depletions within the CD4(+) T-cell repertoire that are not immediately restored by antiviral or immune-based therapies [J].
Connors, M ;
Kovacs, JA ;
Krevat, S ;
GeaBanacloche, JC ;
Sneller, MC ;
Flanigan, M ;
Metcalf, JA ;
Walker, RE ;
Falloon, J ;
Baseler, M ;
Stevens, R ;
Feuerstein, I ;
Masur, H ;
Lane, HC .
NATURE MEDICINE, 1997, 3 (05) :533-540
[10]   Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine [J].
deJong, MD ;
Veenstra, J ;
Stilianakis, NI ;
Schuurman, R ;
Lange, JMA ;
deBoer, RJ ;
Boucher, CAB .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (11) :5501-5506